Annual Meeting December 2025 For personal use only NASDAQ: AVR | ASX: AVR Disclaimer Forward-Looking Statements This presentation (including oral commentary that accompanies this presentation) contains forward-looking statements, including statements related to our business, products and clinical trials and studies. Any statements about our expectations, beliefs, plans, predictions, forecasts, objectives, assumptions, or future events or performance are not historical facts and may be forward-looking. In so ...

Core Insights - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] Group 1 - The article suggests that users may face blocks if ad-blockers are enabled, indicating a need to disable them for proper access [1]

Core Insights - Medtronic has received FDA clearance for its Hugo robotic-assisted surgery (RAS) system for urologic procedures, enhancing options for hospitals and surgeons in the U.S. [1] - The Hugo RAS system aims to address challenges in robotic surgery capacity and access, providing a versatile platform for minimally invasive care [1] Group 1: Product Features - The Hugo RAS system features a modular design that allows robotic arms to be easily moved and shared across different care settings, maximizing utilization and providing flexibility for surgeons [1] - It integrates with the Touch Surgery ecosystem, offering pre-operative training tools, remote tele-proctoring, and AI-powered post-operative insights, facilitating continuous improvement in surgical practices [1] - Medtronic is the only company that meets surgeon needs across all surgical modalities, providing access to world-class robotic training and trusted technologies [1] Group 2: Market Impact - The Hugo RAS system is indicated for minimally invasive urologic procedures such as prostatectomy, nephrectomy, and cystectomy, which account for approximately 230,000 surgeries annually in the U.S. [1] - The system has been utilized in tens of thousands of surgeries across more than 30 countries, indicating its global acceptance and potential for expansion in the U.S. [1] - Medtronic plans to extend the Hugo RAS system's applications to additional surgical specialties, including general and gynecologic procedures, following its initial urology clearance [1]

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Inspire Medical Systems, Inc. (NYSE: INSP). Shareholders who purchased shares of INSP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/inspire-medical-systems-inc-loss-submission-form/?id=179479&from=3  CL ...

Core Insights - Picard Medical, Inc. is the parent company of SynCardia Systems LLC, which produces the world's first total artificial heart approved by both the U.S. FDA and Health Canada [1][3] - CEO Patrick NJ Schnegelsberg will present data on the Emperor Total Artificial Heart at the CSI Focus D-HF conference in Frankfurt, Germany, on December 6, 2025 [1][2] Company Overview - Picard Medical, Inc. is based in Tucson, Arizona, and is a leader in total artificial heart technology for patients with end-stage heart failure [3] - The SynCardia Total Artificial Heart (STAH) is the only commercially available artificial heart in the U.S. and Canada, having been implanted over 2,100 times across 27 countries, making it the most widely used and studied artificial heart globally [3]

Summary of Merit Medical Systems FY Conference Call Company Overview - **Company**: Merit Medical Systems (NasdaqGS: MMSI) - **Industry**: Medical Device Industry - **Key Executives**: CEO Martha Aronson, CFO Raul Parra Core Points and Arguments 1. **Leadership Transition**: Martha Aronson has recently joined Merit Medical, bringing nearly 30 years of experience in the medical device industry, including roles at Medtronic, Hillrom, and Ecolab [2][5][6] 2. **Growth Strategy**: Merit Medical aims to continue its growth through both organic investments and acquisitions, with ongoing initiatives planned through the end of 2026 [5][10] 3. **Executive Leadership Team**: A new executive leadership team has been formed to focus on strategic planning for growth beyond 2026 [6][10] 4. **Financial Guidance**: Merit Medical is confident in achieving its Continuous Growth Initiatives (CGI) goals, which include a revenue CAGR of 5%-7% and operating margins of 20%-22% [15][18] 5. **Wrapsody Product Launch**: The recent launch of Wrapsody is progressing well, with adjustments made to pricing strategies to enhance market penetration [25][27][29] 6. **Market Dynamics**: The company is navigating challenges in the China market, with volume growth remaining strong despite a decrease in sales percentage due to volume-based purchasing [56][57] 7. **OEM Business Performance**: The OEM segment is expected to grow in the mid to high single digits, with current performance aligning with expectations [63] 8. **M&A Strategy**: The M&A strategy will evolve to be more intentional, focusing on strategic fits that enhance the offerings for existing physician groups [64][66] Additional Important Insights 1. **Founder Involvement**: Fred Lampropoulos, the founder, will transition to a non-executive chairman role but will remain available for consultation and to leverage his network [12][13] 2. **Wrapsody's Impact on Renal Portfolio**: The Wrapsody product is expected to positively influence the renal therapy portfolio, enhancing sales force engagement with physicians [50][51] 3. **Clinical Data and Pipeline**: Future developments related to Wrapsody will depend on new clinical data and trials, with the company committed to maintaining confidentiality until solid information is available [36][38] 4. **Market Sentiment**: There is a perception that the market may not fully appreciate Merit Medical's consistent performance and growth potential, particularly in light of recent tariff impacts [15][16] 5. **Competitive Landscape**: The company is aware of competitive pressures and is adjusting its strategies accordingly, particularly in pricing and product offerings [29][30] This summary encapsulates the key points discussed during the conference call, highlighting Merit Medical's strategic direction, market challenges, and growth initiatives.

Core Insights - Align Technology, Inc. showcased its latest innovations in digital dentistry at the Greater New York Dental Meeting (GNYDM) 2025, emphasizing its commitment to enhancing treatment planning and patient experiences through advanced technology [1] Company Innovations - Align Technology presented the Align™ Digital Platform, which integrates software, systems, and services for a seamless workflow among doctors, labs, patients, and consumers [1] - The iTero Lumina™ scanner was highlighted for its 3x larger field of view and ability to scan 2x faster, improving efficiency in capturing complex dental cases [1] - The Align™ Oral Health Suite was introduced, featuring tools for personalized oral health reports to enhance patient engagement [1] - Invisalign Smile Architect™ software now includes Multiple Treatment Plans, allowing for side-by-side comparison of orthodontic and restorative options [1] - The iTero™ Design Suite aims to improve practice efficiency and patient experiences by streamlining the design process for in-practice 3D printing [1] - ClinCheck® Signature experience offers a faster, tailored approach to treatment planning, enhancing the overall workflow for dental professionals [1] Educational Initiatives - Align Technology sponsored clinical education sessions led by industry experts, focusing on practice productivity, diagnosis simplification, and modern patient education [1]

One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.Palo Alto Investors fully exited its position in STAAR Surgical Company (STAA +1.74%), reducing its stake by 791,879 shares in the third quarter, a net change of approximately $13.3 million, according to a November 14 SEC filing.What HappenedPalo Alto Investors disclosed in a November 1, SEC filing that it sold out of STAAR Surgical Company during the third quarter. The fund reported a ...

INSPIRE STOCK ALERT: Inspire Medical Systems, Inc. (INSP) Investors Reminded to Contact BFA Law Prior to the January 5 Deadline in Securities Fraud Class ActionDecember 03, 2025 3:36 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 3, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securiti ...

Partner Reed Kathrein ScrutinizingAllegedConcealment of Billing Code Errors and Inventory Glut Driving 80% Guidance CutSAN FRANCISCO,Dec. 3, 2025/PRNewswire/ -- National shareholder rights law firm**Hagens Berman**reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against**Inspire Medical Systems, Inc. (NYSE:[INSP](#financial- modal))**is**January 5, 2026.**The lawsuitallegesthat Inspire Medical and its executives misled investors b ...